Godavari Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh)
Godavari Drugs Ltd · Outcome · 11 Nov 2026, 10:44 pm
Godavari Drugs Ltd - Financial Result for the Quarter ended 30th Sep'26 (Standalone, INR Lakh) ■ Revenue: 2,823 (+5.9% YoY | +1.0% QoQ) ■ EBITDA: 280 (+40.1% YoY | +11.3% QoQ) ■ EBITDA Margin (%): 9.9 (+242 bps YoY | +92 bps QoQ) ■ PAT: 95.7 (-4.3% YoY | -13.7% QoQ) ■ EPS (INR): 0.90 (-32.3% YoY | -18.2% QoQ)
Original exchange filing (PDF)
More announcements from Godavari Drugs Ltd
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Sushma Kakani · 18 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mohit Jaju · 17 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Mukund Kakani · 17 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Aksheit Kakani · 17 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Tanushree Kakani · 17 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Kamala Jaju · 17 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Ghanshyam Jaju · 17 Nov 2026
- The Exchange has received the disclosure under Regulation 29(2) of SEBI (Substantial Acquisition of Shares & Takeovers) Regulations, 2011 for Priyanka Jaju · 17 Nov 2026
